Michal Lotem

18.5k citations
106 papers · 4.9k indexed · 2 hit papers · h-index 29
  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers 39
    • CAR-T cell therapy research 37
    • Cutaneous Melanoma Detection and Management 14
  • Immunology top 1%
    • Immunotherapy and Immune Responses 39
    • Immune Cell Function and Interaction 14
    • T-cell and B-cell Immunology 12
    • Melanoma and MAPK Pathways 24
    • Virus-based gene therapy research 7

Michal Lotem

102 papers receiving 4.8k citations

Hit Papers

Pembrolizumab versus ipilimumab in advanced melanoma (KEY...7682017202620202023250500750

Peers

Michal Lotem
Comparison fields: 5 of 105
  • Oncology 3.4k
  • Immunology 1.8k
  • Molecular Biology 1.9k
  • Ophthalmology 218
  • Cancer Research 308
Replace Bartosz Chmielowski with:
Bartosz Chmielowski United States
Shailender Bhatia United States
Sapna P. Patel United States
Ragini R. Kudchadkar United States
Leah Haworth United States
Eddy C. Hsueh United States
Marcus O. Butler Canada
Danielle Líénard Switzerland
Uwe Trefzer Germany
Gunnar Kvalheim Norway
Michal Lotem relative to Bartosz Chmielowski United States Bartosz Chmielowski's profile →
Citations per field
00.5×1.5×
Bartosz Chmielowski · 1×
Citations per year

Countries citing papers authored by Michal Lotem

Since Specialization
Citations

This map shows the geographic impact of Michal Lotem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Lotem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Lotem more than expected).

Fields of papers citing papers by Michal Lotem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michal Lotem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Lotem. The network helps show where Michal Lotem may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michal Lotem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michal Lotem Line = papers co-authored together Michal Lotem links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20252
3 20242
4 202338
5 20230
6 202363
7 20231
8 202114
9 202172
10 2020111
11 20202
12 2019219
13 201819
14 201812
15 20161
16 201227
17 200980
18 200716
19
Post Hepatectomy Survival of Metastatic Uveal Melanoma Patients
20061
20 20039

About Michal Lotem

Michal Lotem is a scholar working on Oncology, Immunology and Ophthalmology, having authored 106 papers that have together received 4.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (39 papers), Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (37 papers), Melanoma and MAPK Pathways (24 papers), Cutaneous Melanoma Detection and Management (14 papers), Immune Cell Function and Interaction (14 papers), T-cell and B-cell Immunology (12 papers) and Virus-based gene therapy research (7 papers). The work is most often cited by research in Oncology (3.4k citations), Immunology (1.8k citations) and Molecular Biology (1.9k citations). Michal Lotem has collaborated with scholars based in Israel, United States and Australia. Frequent co-authors include Jacob Schachter, Antoni Ribas, Georgina V. Long, Nageatte Ibrahim, Catriona M. McNeil, Adil Daud, Omid Hamid, Ana Arance, Matteo S. Carlino and Caroline Robert. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026